Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma

View ORCID ProfileAmit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, Vithal Madhira, Timothy Bergquist, Yu Raymond Shao, Feifan Liu, Qianqian Song, Jing Su, Shaji Kumar, Benjamin A. Bates, Noha Sharafeldin, Umit Topaloglu the National COVID Cohort Collaborative Consortium
doi: https://doi.org/10.1101/2022.12.07.22283208
Amit Kumar Mitra
1Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL
2Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Auburn University, Auburn, AL
3UAB Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Amit Kumar Mitra
  • For correspondence: akm0060@auburn.edu
Ujjal Kumar Mukherjee
4University of Illinois, Urbana-Champaign, IL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suman Mazumder
1Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL
2Center for Pharmacogenomics and Single-Cell Omics (AUPharmGx), Auburn University, Auburn, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vithal Madhira
5Palila Software LLC, Reno, NV
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Timothy Bergquist
6Sage Bionetworks, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu Raymond Shao
7Duke University Medical Center, NC
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Feifan Liu
8University of Massachusetts Chan Medical School, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qianqian Song
9Wake Forest School of Medicine Winston-Salem, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jing Su
10Department of Biostatistics, Indiana University School of Medicine, Indianapolis, IN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shaji Kumar
11Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Benjamin A. Bates
12Department of Medicine, Rutgers-RWJMS Medical School, New Brunswick, NJ
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noha Sharafeldin
13School of Medicine, University of Alabama at Birmingham, Birmingham, AL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Umit Topaloglu
9Wake Forest School of Medicine Winston-Salem, NC, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Patients with multiple myeloma (MM), an age-dependent neoplasm of antibody-producing plasma cells, have compromised immune systems and might be at increased risk for severe COVID-19 outcomes. This study characterizes risk factors associated with clinical indicators of COVID-19 severity and all-cause mortality in myeloma patients utilizing NCATS’ National COVID Cohort Collaborative (N3C) database. The N3C consortium is a large, centralized data resource representing the largest multi-center cohort of COVID-19 cases and controls nationwide (>16 million total patients, and >6 million confirmed COVID-19+ cases to date).

Our cohort included myeloma patients (both inpatients and outpatients) within the N3C consortium who have been diagnosed with COVID-19 based on positive PCR or antigen tests or ICD-10-CM diagnosis code. The outcomes of interest include all-cause mortality (including discharge to hospice) during the index encounter and clinical indicators of severity (i.e., hospitalization/emergency department/ED visit, use of mechanical ventilation, or extracorporeal membrane oxygenation (ECMO)). Finally, causal inference analysis was performed using the propensity score matching (PSM) method.

As of 05/16/2022, the N3C consortium included 1,061,748 cancer patients, out of which 26,064 were MM patients (8,588 were COVID-19 positive). The mean age at COVID-19 diagnosis was 65.89 years, 46.8% were females, and 20.2% were of black race. 4.47% of patients died within 30 days of COVID-19 hospitalization. Overall, the survival probability was 90.7% across the course of the study. Multivariate logistic regression analysis showed histories of pulmonary and renal disease, dexamethasone, proteasome inhibitor/PI, immunomodulatory/IMiD therapies, and severe Charlson Comorbidity Index/CCI were significantly associated with higher risks of severe COVID-19 outcomes. Protective associations were observed with blood-or-marrow transplant/BMT and COVID-19 vaccination. Further, multivariate cox proportional hazard analysis showed that high and moderate CCI levels, International Staging System (ISS) moderate or severe stage, and PI therapy were associated with worse survival, while BMT and COVID-19 vaccination were associated with lower risk of death. Finally, matched sample average treatment effect on the treated (SATT) confirmed the causal effect of BMT and vaccination status as top protective factors associated with COVID-19 risk among US patients suffering from multiple myeloma.

To the best of our knowledge, this is the largest nationwide study on myeloma patients with COVID-19.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Prior institutional review board approvals were obtained from respective institutions to access the N3C data. Further, all the authors who had access to N3C data in the Enclave and performed analyses were approved by the N3C data Use Request committee to access the limited use dataset (Level 3). The N3C data transfer to NCATS is performed under a Johns Hopkins University Reliance Protocol # IRB00249128 or individual site agreements with NIH. The N3C Data Enclave is managed under the authority of the NIH; information can be found at https://ncats.nih.gov/n3c/resources.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted December 08, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
Amit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, Vithal Madhira, Timothy Bergquist, Yu Raymond Shao, Feifan Liu, Qianqian Song, Jing Su, Shaji Kumar, Benjamin A. Bates, Noha Sharafeldin, Umit Topaloglu
medRxiv 2022.12.07.22283208; doi: https://doi.org/10.1101/2022.12.07.22283208
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Sample average treatment effect on the treated analysis using counterfactual explanation identifies BMT and SARS-CoV-2 vaccination as protective risk factors associated with COVID-19 severity and survival in patients with multiple myeloma
Amit Kumar Mitra, Ujjal Kumar Mukherjee, Suman Mazumder, Vithal Madhira, Timothy Bergquist, Yu Raymond Shao, Feifan Liu, Qianqian Song, Jing Su, Shaji Kumar, Benjamin A. Bates, Noha Sharafeldin, Umit Topaloglu
medRxiv 2022.12.07.22283208; doi: https://doi.org/10.1101/2022.12.07.22283208

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10021)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (74)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4833)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)